What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional study in the UK DOI Creative Commons

Nadja Auerbach,

Vivian Liu, David Huang

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Abstract Introduction Obesity is a critical public health challenge globally. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in weight loss, but their adoption influenced by various individual and societal factors. This study sought to examine awareness, motivations barriers of GLP-1RAs the UK, with focus on demographic differences. Methods A cross-sectional survey 1,297 UK adults was conducted using an electronic questionnaire distributed via social media, online platforms personal networks. The assessed characteristics, perceptions use GLP-1RAs. Data were analysed chi-squared tests, Kruskal-Wallis tests relative risk ratios (RRRs) from multinomial logistic regression. p-value <0.05 considered significant. Results Significantly higher awareness observed among those attempting loss past year (85.7% vs. 14.3%, p < 0.001). [vv1] Women more most likely report both (87.2% 68.2%, 0.001) excellent understanding (20.0% 7.5%, Main information sources included news (60.1%) media (50.2%). Only 9.0% first learned about healthcare providers. Past current users less than non-users express scepticism safety efficacy, 6.91 times strongly disagree that "risks outweigh benefits" (RRR 6.91; 95% CI 4.32–11.05; 7.33 "there not enough evidence suggest are safe" 7.33; 4.05–13.27; 91.0% current/past-users indicated they would recommend friend struggling weight. Conclusion Concerns safety, cost potential side effects remain GLP-1RA adoption. Current/past statements scepticism, however highlights need for improved education around efficacy. [vv1]check

Language: Английский

Orexins mitigate obesity‐associated dysfunctions in mice DOI Creative Commons
Anne Blais, Isabelle Denis, Mireille Andriamihaja

et al.

Obesity, Journal Year: 2024, Volume and Issue: 32(10), P. 1897 - 1909

Published: Sept. 24, 2024

Abstract Objective Obesity is a chronic disease that affects more than 400 million adults with severe comorbidities. The search for new treatments to reduce its negative consequences necessary. Orexins are hypothalamic neuropeptides involved in various physiological processes related obesity. aim of this study was investigate the orexin‐A treatment mouse models. Methods Female wild‐type C57BL/6 mice were obesity‐prone or obesity‐resistant and deficient orexin receptors fed high‐fat diet. Glucose tolerance, indirect calorimetry, expression brain receptors, microglial activation, microbiota determined evaluate role orexins on metabolic flexibility. Results Orexin‐A reduces weight gain mice. This reduction associated decrease body fat, food intake, steatosis, insulin resistance, as well alterations intestinal composition. A decreased intake also observed hypothalamus. Conclusions Our data support notion receptor signaling different aspects energy metabolism can mitigate several dysfunctions obesity, suggesting represent targets obesity treatment.

Language: Английский

Citations

1
Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps DOI Creative Commons
Yaanu Jeyakumar, Lisa Richardson, Shohinee Sarma

et al.

BMJ Global Health, Journal Year: 2024, Volume and Issue: 9(11), P. e017177 - e017177

Published: Nov. 1, 2024

Introduction Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm obesity treatment. Diversity in trial participation is imperative considering that disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate representation racialised ethnically diverse randomised controlled trials (RCTs) for obesity. Methods searched PubMed/Embase/ClinicalTrials.gov. Prevalence each racial/ethnic group was compared relation USA, Canada, UK, Brazil South Africa. The geographical locations sites were extracted. Results 27 RCTs identified (n=21 547 participants). Meta-analyses prevalence demonstrated vast predominance white/Caucasians (79%) with smaller proportion blacks (9%), Asians (13%), Indigenous (2%) Hispanics (22%). gaps evidenced by significantly under-represented non-white individuals these as general population USA (−23%, p=0.002) Canada (−34%, p<0.0001), reaching an alarming gap −58% striking under-representation −68% Similar discrepancies proportions blacks, peoples reference nations found. Moreover, (n=1859) predominately located high-income countries (84.2%), sharp contrast global predominantly low-income middle-income countries. Conclusion There are multiethnic These data highlight need broader reform research process order ultimately address health inequities.

Language: Английский

Citations

1
Relationship of female pelvic floor muscle function and body composition: cross-sectional study DOI
Ana Jéssica dos Santos Sousa, Stela Márcia Mattiello, Patrícia Driusso

et al.

Archives of Gynecology and Obstetrics, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 27, 2024

Language: Английский

Citations

0
Dimorphic Nature of Adipose Tissue and Role of Herbal Extracts in Lipids Metabolism DOI Creative Commons
Svetlana Dzitoyeva

Obesity and metabolism, Journal Year: 2024, Volume and Issue: 21(4), P. 365 - 372

Published: Oct. 2, 2024

Adipose tissue, known as body fat, plays a crucial role in human health and disease. Traditionally viewed storage site for excess energy advances medical research have shown the complex dynamic nature of adipose highlighting its critical regulation metabolism, hormone production, immune response. tissue is subdivided into two types – lipids accumulating white (WAT) brown (BAT), color which determined by load mitochondria; beige (BeAT) mix WAT BAT cells. This review aims to explore multifaceted aspects WAT, focusing on key areas: diverse cell comprising their unique functions, major genes expressed secreted from cells, inflammation, sex-specific differences transcriptomes. Understanding intricate dynamics context factors having systemic effects, including inflammatory response, essential, given central maintaining balance metabolic homeostasis issues like obesity, type 2 diabetes, cardiovascular diseases. Examining adipocyte-specific transcriptomes gives an understanding characteristics these The dimorphic not only influences fat distribution but also affects disease susceptibility response treatment. Additionally, this will cover increasingly recognized intriguing effects plant extracts adipogenesis, offer potential therapeutic avenues treating obesity related disorders.

Language: Английский

Citations

0
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA DOI Open Access

T. Freitas,

Frederico Lucas de Oliveira Mota,

Anna Clara Mafort Pinheiro

et al.

Revista Foco, Journal Year: 2024, Volume and Issue: 17(10), P. e6522 - e6522

Published: Oct. 17, 2024

Introdução: A obesidade é uma doença crônica com causas multifatoriais que afeta a saúde e diagnosticada pelo Índice de Massa Corporal (IMC). O tratamento envolve abordagens multidisciplinares, incluindo mudanças estilo vida, atividade física, farmacoterapia e, em casos graves, cirurgia bariátrica. Objetivo: Analisar indicações, mecanismo ação, efeitos eficácia das terapias farmacológicas utilizadas no da obesidade. Metodologia: Utilizando descritores específicos, foram realizadas buscas nas plataformas PubMed Portal Capes publicações nos últimos 5 anos, sobre fármacos usados na Avaliados 219 artigos, destes selecionados analisados 32 artigos os protocolos do Ministérios Saúde Sociedade Brasileira Pediatria. Resultados: Os disponíveis para tratar obesidade, sua maioria, são eficientes reduzir significativamente o peso, melhora dos sintomas clínicos comorbidades associadas à sejam cardiovasculares, metabólicas, ortopédicas ou respiratórias. Alguns mostraram-se capazes diretamente resistência insulínica, porém, adversos cada classe terapêutica interações medicamentosas devem ser consideradas. Conclusão: desempenha papel significativo perda manutenção viabilizando desejado controle ponderal, prevenindo complicações melhoria qualidade quando associados definitivas vida. Além disso, deve-se atentar aos potenciais terapêutica.

Citations

0
Lifestyle and BMI Changes after the Release of COVID-19 Restrictions: Do Humans Go ‘Back to Normal’? DOI Creative Commons

B Krznar,

Marijan Vilenica,

Frank Rühli

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(11), P. 858 - 858

Published: Oct. 23, 2024

Humans adapt their life history strategy and lifestyle behavior to the environment. The social restrictions during COVID-19 pandemic in years 2020-2021 led changes diet physical activity habits large parts of populations worldwide. Additionally, many people reported an increase body weight pandemic. We investigated how quality, activity, BMI changed since end Switzerland (2019-2023). assessed using a standardized questionnaire. measured anthropometry stadiometer balance medical bioimpedance analyzer. Our results show stable men women In both sexes, quality levels did not change significantly this time. Among women, age were associated with BMI, while men, apart from high living agglomeration BMI. Overall, we find evidence for transient "unhealthier" immediately after However, found constituent sex differences determinants. could indicate higher resilience highly educated persons might contribute more personalized approaches prevent obesity.

Language: Английский

Citations

0
Visual Analysis of Related Literature on Acupuncture Treatment for Obesity Based on Web of Science DOI Open Access

俊辉 王

Journal of Clinical Personalized Medicine, Journal Year: 2024, Volume and Issue: 03(04), P. 1998 - 2012

Published: Jan. 1, 2024

Language: Английский

Citations

0
What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional study in the UK DOI Creative Commons

Nadja Auerbach,

Vivian Liu, David Huang

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Abstract Introduction Obesity is a critical public health challenge globally. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in weight loss, but their adoption influenced by various individual and societal factors. This study sought to examine awareness, motivations barriers of GLP-1RAs the UK, with focus on demographic differences. Methods A cross-sectional survey 1,297 UK adults was conducted using an electronic questionnaire distributed via social media, online platforms personal networks. The assessed characteristics, perceptions use GLP-1RAs. Data were analysed chi-squared tests, Kruskal-Wallis tests relative risk ratios (RRRs) from multinomial logistic regression. p-value <0.05 considered significant. Results Significantly higher awareness observed among those attempting loss past year (85.7% vs. 14.3%, p < 0.001). [vv1] Women more most likely report both (87.2% 68.2%, 0.001) excellent understanding (20.0% 7.5%, Main information sources included news (60.1%) media (50.2%). Only 9.0% first learned about healthcare providers. Past current users less than non-users express scepticism safety efficacy, 6.91 times strongly disagree that "risks outweigh benefits" (RRR 6.91; 95% CI 4.32–11.05; 7.33 "there not enough evidence suggest are safe" 7.33; 4.05–13.27; 91.0% current/past-users indicated they would recommend friend struggling weight. Conclusion Concerns safety, cost potential side effects remain GLP-1RA adoption. Current/past statements scepticism, however highlights need for improved education around efficacy. [vv1]check

Language: Английский

Citations

0